Your browser is no longer supported. Please, upgrade your browser.
VERU Veru Inc. daily Stock Chart
Veru Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own1.30% Shs Outstand65.37M Perf Week-4.49%
Market Cap216.66M Forward P/E- EPS next Y-0.05 Insider Trans0.80% Shs Float50.21M Perf Month-5.90%
Income-10.00M PEG- EPS next Q-0.03 Inst Own16.30% Short Float0.61% Perf Quarter4.93%
Sales39.00M P/S5.56 EPS this Y57.30% Inst Trans22.85% Short Ratio0.51 Perf Half Y-12.36%
Book/sh0.48 P/B6.65 EPS next Y61.50% ROA-18.30% Target Price- Perf Year41.15%
Cash/sh0.04 P/C83.33 EPS next 5Y- ROE-31.10% 52W Range1.67 - 4.74 Perf YTD-4.78%
Dividend- P/FCF- EPS past 5Y-33.60% ROI-13.80% 52W High-32.70% Beta0.39
Dividend %- Quick Ratio0.70 Sales past 5Y5.40% Gross Margin69.60% 52W Low91.02% ATR0.24
Employees386 Current Ratio1.00 Sales Q/Q41.40% Oper. Margin-14.00% RSI (14)42.31 Volatility4.76% 7.52%
OptionableYes Debt/Eq0.43 EPS Q/Q80.70% Profit Margin-25.50% Rel Volume0.86 Prev Close3.19
ShortableYes LT Debt/Eq0.22 EarningsMay 13 BMO Payout- Avg Volume601.97K Price3.19
Recom1.70 SMA20-4.87% SMA50-9.21% SMA2002.86% Volume515,276 Change0.00%
Jan-21-20Reiterated H.C. Wainwright Buy $4.50 → $6
Mar-20-19Initiated Oppenheimer Outperform $5
Jul-03-18Initiated Maxim Group Buy
Jul-06-20 09:45AM  
Jun-29-20 08:30AM  
Jun-25-20 08:44AM  
Jun-23-20 09:11PM  
Jun-19-20 08:30AM  
Jun-12-20 09:45AM  
May-26-20 08:30AM  
May-15-20 12:39PM  
May-13-20 03:30PM  
May-12-20 12:00PM  
May-06-20 08:30AM  
May-05-20 08:30AM  
Feb-26-20 08:30AM  
Feb-12-20 06:30AM  
Feb-05-20 08:30AM  
Jan-30-20 11:40AM  
Jan-29-20 07:01AM  
Jan-21-20 08:30AM  
Jan-14-20 07:55AM  
Jan-13-20 08:00AM  
Jan-09-20 08:56AM  
Dec-23-19 06:24PM  
Dec-17-19 07:09AM  
Dec-16-19 10:37AM  
Dec-12-19 06:30AM  
Dec-05-19 08:30AM  
Oct-10-19 01:43PM  
Oct-02-19 06:30AM  
Sep-04-19 10:53AM  
Aug-28-19 08:30AM  
Aug-27-19 08:30AM  
Aug-08-19 06:30AM  
Aug-01-19 09:19PM  
Jul-31-19 01:50PM  
Jul-26-19 03:06PM  
Jul-18-19 02:07PM  
Jul-08-19 09:32AM  
Jun-26-19 08:30AM  
Jun-04-19 08:00AM  
May-28-19 08:30AM  
May-24-19 01:19PM  
May-15-19 06:30AM  
May-08-19 08:30AM  
May-06-19 07:02AM  
May-01-19 10:33AM  
Apr-05-19 02:47PM  
Mar-12-19 08:00AM  
Mar-06-19 01:23PM  
Feb-13-19 06:30AM  
Feb-12-19 08:00AM  
Feb-06-19 10:31AM  
Jan-22-19 08:30AM  
Jan-18-19 08:26AM  
Jan-15-19 08:00AM  
Jan-14-19 08:00AM  
Dec-13-18 06:30AM  
Dec-06-18 08:30AM  
Dec-03-18 02:33PM  
Nov-13-18 08:30AM  
Oct-01-18 07:30AM  
Sep-27-18 05:00PM  
Sep-26-18 04:01PM  
Sep-12-18 08:00AM  
Aug-30-18 08:00AM  
Aug-29-18 08:00AM  
Aug-28-18 08:00AM  
Aug-27-18 08:00AM  
Aug-14-18 06:30AM  
Aug-07-18 04:08PM  
Jun-12-18 08:30AM  
May-30-18 08:30AM  
May-17-18 08:30AM  
May-09-18 06:30AM  
May-03-18 08:40AM  
Mar-22-18 08:30AM  
Mar-16-18 08:30AM  
Mar-14-18 08:30AM  
Mar-05-18 08:30AM  
Feb-14-18 06:30AM  
Feb-07-18 08:30AM  
Feb-06-18 08:30AM  
Jan-16-18 07:30AM  
Jan-02-18 07:00AM  
Dec-14-17 02:15PM  
Dec-11-17 08:30AM  
Nov-21-17 05:59PM  
Nov-13-17 08:30AM  
Oct-03-17 08:30AM  
Sep-28-17 10:21AM  
Veru Inc., an oncology and urology biopharmaceutical company, engages in developing novel medicines for prostate cancer treatment and prostate cancer supportive care. The company's oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a development Phase 1b/2 for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing androgen deprivation therapies; and VERU-100, a GnRH antagonist that is in planned Phase 2 clinical trial for the palliative treatment of advanced prostate cancer. Its urology specialty drug candidates are TADFIN, a tadalafil and finasteride combination of tablets and capsules for the treatment of men with lower urinary tract symptoms; and Tamsulosin XR capsules, which are tamsulosin capsules for treating benign prostatic hyperplasia. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation. Its customers primarily include international agencies, government health agencies, ministries of health, and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FISCH HARRYDirectorFeb 21Buy4.471,0004,470859,025Feb 24 12:31 PM
FISCH HARRYDirectorFeb 20Buy4.511,0004,510858,025Feb 21 11:44 AM
Socorro JesusDirectorFeb 19Buy4.275,00021,35032,500Feb 19 05:30 PM
Socorro JesusDirectorDec 19Buy2.805,00014,00027,500Dec 20 12:53 PM
STEINER MITCHELL SHUSTERPresident and CEODec 05Sale2.2216,59036,8467,434,767Dec 06 11:53 AM
STEINER MITCHELL SHUSTERPresident and CEODec 04Sale2.208,41018,4947,451,357Dec 06 11:53 AM